Early Copaxone treatment may delay clinically definite MS

A board to discuss the Multiple Sclerosis modifying drug Copaxone

Early Copaxone treatment may delay clinically definite MS

Postby MSUK » Sat Oct 16, 2010 2:18 am

Image

Teva Pharmaceutical Industries Ltd. announced new data from the five-year extension of the PreCISe study demonstrating that earlier initiation of treatment with Copaxone(R) (glatiramer acetate injection) in patients presenting with first signs of multiple sclerosis (MS), provided greater effects in delaying conversion to clinically definite MS (CDMS) compared to later treatment initiation after diagnosis of CDMS or after three years on the study.

Early treatment with Copaxone(R) reduced the risk of progression to CDMS by 41 percent (p=0.0005) compared with delayed treatment and delayed time to conversion to CDMS by almost three years or 972 days... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1767
MS-UK - http://www.ms-uk.org/
User avatar
MSUK
Family Elder
 
Posts: 2142
Joined: Wed Oct 14, 2009 3:00 pm

Advertisement

Return to Copaxone

 


  • Related topics
    Replies
    Views
    Last post

Who is online

Users browsing this forum: No registered users


Contact us | Terms of Service